Articles tagged with Cancer Patients
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
The study reveals a narrowing gap between cancer profiles in China and the USA, with converging trends in lung, breast, and colorectal cancers. China's cancer burden is expected to rise, while the US has seen reduced rates since the 1990s due to effective prevention strategies.
The ATHENA-MONO trial shows significant improvements in progression-free survival for patients with advanced ovarian cancer treated with Rubraca as maintenance therapy. Benefit was observed across all patients, including those with homologous recombination deficiency and BRCA mutant tumors.
The NCCN Annual Conference focuses on the cancer patient journey, featuring state-of-the-art practice algorithms, updates to clinical guidelines, and new therapies. Leading experts present treatment recommendations for various cancer types, including breast, colorectal, and lung cancer.
A study analyzed perspectives on personal health records from cancer patients and providers, highlighting the need for discussions about record uses. Implementing PHRs more widely, tailoring them to specific conditions, and making them user-friendly are next steps to improve patient-centered care.
A new algorithm using AI and data analytics predicts bowel cancer patients' length of stay, readmission rates, and mortality, enabling healthcare providers to optimize patient care. The technology has been proven effective with an accuracy rate above 80%, and further development is planned with larger datasets.
Researchers at Penn Medicine have developed a new approach to alter immune cells for CAR T cell therapy in just 24 hours, cutting manufacturing time from nine to 14 days. This could make the therapy more cost-effective and accessible to more patients.
Dr. Elaine S. Jaffe is being recognized for her pioneering work in hematopathology, including the discovery of novel pathological entities and her development of standardized diagnostic criteria for lymphoma and leukemia. She has also made significant contributions to advancing cancer research, diagnosis, treatment, and prevention.
A new study from the University of Eastern Finland shows that liquid biopsy can detect cancer mutations months before recurrent breast cancer is detected. This method uses biomarkers released by cancer cells in serum samples to assess changes in intratumoural heterogeneity and provide a more accurate clinical picture.
Researchers develop innovative non-contact agitation technology to assess motility and invasive capacity of cancer cells in tissue sections. The study reveals significant increases in Rac/Cdc42 activity in tumor areas, with stronger correlations found in advanced cancer stages.
A study published in JAMA Network Open found that half of all women will experience at least one false positive mammogram over a decade of annual breast cancer screening with 3D mammography. The risk of false positives is lower for women screened every other year, and non-dense breasts also show a lower false positive risk.
Dr. Tony Hunter's groundbreaking work on protein tyrosine phosphorylation has led to the development of targeted cancer therapies and a deeper understanding of cancer biology. His discovery has been recognized with numerous awards, solidifying his legacy in cancer research.
Researchers collected hundreds of cerebrospinal fluid samples from patients with Diffuse Midline Glioma, tracking changes in cell-free tumor DNA over time. The findings suggest that this method could provide data about tumors sooner than MRIs alone, allowing clinicians to address aggressive brain cancer more effectively.
Scientists have identified diagnostic features of circulating tumour DNA (ctDNA) in blood samples, which can predict treatment response and patient outcome in aggressive lymphoma. The study reveals significant heterogeneity among patients, with high ctDNA levels associated with poorer survival rates.
Researchers at TTUHSC will investigate common mechanisms of resistance and sensitivity in alternate telomere lengthening (ALT) cancers, with a focus on targeting ATM kinase inhibitors for therapy. The team aims to develop clinical trials for patients with ALT+ cancers.
The FDA has approved a novel combination therapy of relatlimab and nivolumab for patients with metastatic or inoperable melanoma. The treatment significantly delayed cancer progression time compared to nivolumab alone. LAG-3 blockade reinvigorated T cell anti-tumor activity, establishing the pathway as the third immune checkpoint target.
Researchers at Karolinska Institutet identified a novel protein mechanism that inhibits tumour growth in ER-negative breast cancer, leading to improved prognosis. High levels of GIT1 were associated with reduced tumour growth and better outcomes in ER-negative patients.
The American Association for Cancer Research (AACR) announced its newly elected class of Fellows of the AACR Academy, recognizing distinguished scientists who have propelled innovation and progress against cancer. The 2022 class consists of 33 luminaries from various scientific disciplines.
A team of researchers led by Tejas Patil is investigating how the EGFR and MET signaling pathways contribute to treatment resistance in RET-positive lung cancer. The study aims to determine whether combining a RET-targeted therapy with amivantamab, a bi-specific antibody blocking both pathways, can improve patient outcomes.
The study found that homologous recombination repair mutant type (HRRmt) was prognostic of progression-free survival and predictive for olaparib activity in women with recurrent platinum-sensitive ovarian cancer. Patients with BRCA mutations showed clinically significant activity when treated with experimental drugs.
Researchers found that genetic ancestry is associated with differences in biology of acute lymphoblastic leukemia (ALL) and is an independent factor contributing to treatment outcomes. Children from East Asian and South Asian backgrounds had better survival rates than Caucasian children, with Indian children having the best outcomes.
A new analysis of cases in the National Cancer Database finds that younger patients (less than 50 years old) with acute appendicitis are at increased risk of developing cancer of the appendix. The study suggests that patients under 40 may want to undergo surgery to rule out cancer.
Researchers have discovered an essential role of LCOR in enabling cancer cells to present tumour antigens, making them visible to the immune system. This approach increases the success of immunotherapy in triple-negative breast cancer, a subtype with low treatment response rates.
The ECOG-ACRIN Cancer Research Group has opened a new treatment arm in the NCI-MATCH trial for patients with DNA mismatch repair deficiency and LAG-3 expression. The trial is evaluating two immunotherapy combinations: relatlimab plus nivolumab and dabrafenib plus trametinib, both targeting BRAF mutations.
A clinical trial found that genomic sequencing enabled 107 patients to receive matched therapy, increasing treatment options for those experiencing cancer relapse. The study identified previously unknown mutations and showed promise for using circulating tumor DNA to identify targetable alterations.
Researchers at Weill Cornell Medicine have found that an enzyme called ART1 can modify a receptor on tumor-fighting immune cells, triggering their death. Blocking ART1 increased the presence of these immune cells within tumors and slowed or stopped tumor growth in animal models.
A new retrospective cohort study analyzed data from over 4.5 million adult cancer patients, revealing a significantly higher risk of cardiovascular mortality and events following a new cancer diagnosis. The study highlights the need for a collaborative approach to healthcare for cancer patients and survivors.
Two clinical trials will report groundbreaking data on adjuvant olaparib for germline BRCA1/2 associated breast cancer and pembrolizumab for early-stage non-small cell lung cancer. These treatments aim to improve survival rates and reduce recurrence.
The Southeastern Consortium for Lung Cancer Health Equity aims to address disparities in lung cancer screening among racially and ethnically diverse populations. Researchers will develop more precise methods for identifying those at highest risk of lung cancer diagnoses.
A study of insurance claims data found that state laws governing opioid prescribing had a negligible effect on opioid prescribing trends. The authors suggest that shifting clinical guidelines, professional norms, or other factors may be driving the decline in opioid prescribing. In contrast, a post-hoc analysis of an ASPREE trial found...
Research found a significant drop in new cancer diagnoses during the COVID-19 pandemic, particularly for screening cancers like breast, cervical, and colorectal cancer. The study estimates around 12,600 cancers went undetected between March 2020 and September 2020.
A comprehensive review of over 60 studies confirms that COVID vaccination is around 80% effective in protecting people with cancer against SARS-CoV-2 infection. The mRNA vaccines were found to be the most effective, and multiple vaccinations are recommended for better protection.
Researchers found that hydroxychloroquine inhibits pathways that drive resistance to cisplatin in head and neck cancers, restoring tumor-killing effects. The study paves the way for a clinical trial combining hydroxychloroquine and cisplatin to treat chemotherapy-resistant patients.
A Moffitt study found that COVID-19 vaccination led to seroconversion in most cancer patients, but with differing antibody response rates among various cancer types and treatments. Patients with blood cancers had lower seroconversion rates compared to those with solid tumors, highlighting the need for personalized immune responses.
A CHOP-led study found bortezomib significantly improved overall survival in children and young adults with newly diagnosed T-cell lymphoblastic lymphoma. The trial also showed that intensifying the chemotherapy regimen allowed for elimination of radiation in nearly all patients, resulting in excellent outcomes.
A new study found that dual-eligible patients for Medicare and Medicaid have poorer outcomes and higher costs after cancer surgery, even in high-quality hospitals. These patients are more likely to experience complications, longer hospital stays, and lower chances of going home instead of a nursing facility.
Researchers at the University of South Australia have developed a new way to deliver chemotherapy drugs, using liposomal formulations that target tumors more effectively. This breakthrough could improve treatment outcomes for thousands of cancer patients, reducing side effects and improving quality of life.
A study led by University of Illinois Chicago researchers found that structural racism can result in poorer leukemia outcomes for Black and Hispanic patients. Neighborhood disadvantage was a significant predictor of leukemia-specific death, accounting for nearly all the Black-white disparity in AML-related death.
A U-M study defines how a cytokine and fatty acid combination triggers ferroptosis, a type of cell death previously studied with synthetic molecules. This natural mechanism could make immunotherapy treatments more effective, particularly for cancers where the treatments currently work for only about 30% of patients.
A new fluorescent DNA label has been developed to visualize disrupted DNA architecture in cancer cells, with promising results for improved cancer diagnoses and risk stratification. The study showed that the label can distinguish normal tissue from precancerous and cancerous lesions.
A study of nearly 40,000 Medicare beneficiaries found racial disparities in the use of MRI among Black and white patients with new prostate cancer diagnoses. The study identified factors such as insurance coverage, socioeconomic status, and geographic location that contribute to these disparities.
The Cancer Prevention & Research Institute of Texas has awarded a grant extension to Dr. Rakhshanda Rahman, allowing her to provide no-cost mammograms and Pap smears to underinsured and uninsured women in the Permian Basin. The program aims to address high cervical cancer incidence and mortality rates in West Texas.
Researchers at Johns Hopkins Medicine discovered 110 genes, circular RNAs, lipids and metabolites that differ between medulloblastoma patients' cerebrospinal fluid and healthy controls. These findings provide proof of principle for novel biomarkers to detect and track the disease.
Scientists have discovered a new therapeutic approach to aid the immune system in fighting cancer, offering hope for better solutions for patients. Researchers found that blocking the EP4 molecule can 'free' the immune system and restore its cancer-fighting functions.
Computer simulations reveal metformin's effectiveness in targeting diabetes and some cancers, but also its negative consequences for others. Researchers emphasize the need for precision medicine to individualize treatment based on patient profiles.
A University of Cincinnati clinical trial showed promising results for patients with intermediate risk head and neck cancer when an immunotherapy drug, pembrolizumab, was added to standard treatment regimens. The study found improved one-year disease-free survival rates compared to historical controls.
A new study found that traditional Chinese medicine Shengmai Yin increases the sensitivity of cancer cells to radiation, reducing radioresistance. By altering DNA methylation status, SMY enhances the efficacy of radiation therapy and reduces side effects.
A new phase II trial found that mid-treatment PET scans can help determine if patients with p16-positive oropharynx cancer can receive a lower dose of radiation therapy without compromising cancer control. The study reported fewer short-term side effects in patients who received de-escalated therapy.
Researchers at UVA Cancer Center have made a groundbreaking discovery about the EP300 gene and its role in small-cell lung cancer. The study found that the gene makes a protein with properties that can both foster and prevent tumor formation, providing a new potential target for treatment.
A systematic review found that intersectional identities are associated with lower diagnostic screening and reception of preventative services. Patients with these identities face increased distrust of the healthcare system and negative cancer outcomes.
A new AI model combines multiple machine learning methods to accurately detect thyroid cancer and predict treatment outcomes from routine ultrasound images. The multimodal platform achieved high accuracy rates in detecting malignancies and predicting pathological stage and genomic mutations.
A blood test detecting circulating tumor DNA can accurately predict recurrence of HPV-driven oropharyngeal cancer following treatment. The biomarker test may detect recurrent disease earlier than imaging or other standard methods, allowing physicians to personalize treatment more quickly for patients whose cancer returns.
A new synthetic substance, PECS-101, has been shown to prevent neuropathic pain caused by chemotherapy while improving cancer treatment outcomes. The study, conducted in mice, found that PECS-101 had no adverse effects and did not cause dependence.
Researchers investigated COVID-19 mortality in adult cancer patients, finding that systemic treatments and comorbidities played a role in increased risk. The study analyzed 2,500 patients and identified specific tumor subtypes associated with higher mortality rates.
Scientists have developed a new therapy called CINDELA, which employs CRISPR-Cas9 to kill cancer cells while leaving normal tissues intact. The treatment targets specific mutations found in cancer cells and induces cell death through DNA double-strand breaks.
New study reveals that T-cell responses against the SARS-CoV-2 spike protein can predict protection against infection. In healthy individuals, T cells with a specific cytokine profile offered immunity against COVID-19. In contrast, cancer patients showed lower T-cell responses and increased susceptibility to infection.
Scientists have discovered a new subtype of relapsed pediatric AML characterized by a specific gene mutation called UBTF exon 13 tandem duplication (UBTF-TD), which is associated with poor outcomes and an increased incidence of minimal residual disease. This mutation can be used to identify high-risk patients and guide treatment.
A team of researchers has discovered blood biomarkers that can predict patient response to immunotherapy treatment for melanoma. The study found that patients with increased lactate levels and specific lipid and amino acid metabolites were more likely to respond to treatment.
A recent study published in JAMA Network Open found that the COVID-19 pandemic led to fewer early-stage and more late-stage breast cancer diagnoses. Researchers at UC San Diego Health surveyed patients with breast and colorectal cancers in 2019 and 2020, finding a significant increase in stage IV diagnoses.
Researchers from National Cancer Centre Singapore have found a potential new strategy to treat peritoneal carcinomatosis, a metastatic form of intra-abdominal cancer. The team identified targeting ascites, excess fluid in the abdomen, as a way to remove fuel that drives cancer growth.
Results from the Phase III EMPOWER trial demonstrate the efficacy of PD-1 inhibitor cemiplimab in improving overall survival for women with recurrent and/or metastatic cervical cancer. The study showed a 31% lower risk of death in patients receiving cemiplimab compared to chemotherapy.